iolinq

ioLinq is a private biotechnology company dedicated to developing next-generation immuno-oncology treatments that overcome resistance to current checkpoint inhibitors. Based in Lexington, Massachusetts, the company utilizes a proprietary discovery platform to identify novel immune regulatory pathways and targets. Its lead candidate, IO-101, is a humanized monoclonal antibody designed to block PVRIG (CD112R), a checkpoint protein that limits T-cell and NK-cell activity in the tumor microenvironment. By targeting the DNAM-1 axis, ioLinq aims to provide potent anti-tumor responses, particularly in patients who do not respond to PD-1/PD-L1 therapies. The company is led by industry veterans with extensive experience in drug discovery and clinical development.